Real-world study of standard-dose hetrombopag in aplastic anemia

Phase 4, open-label, single-arm trial of hetrombopag in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence and degree of hepatic dysfunction within 4-6 months of standard-dose hetrombopag treatment, Incidence and degree of renal dysfunction within 4-6 months of standard-dose hetrombopag treatment and 1 more. Planned start Aug 2024; status: not yet recruiting.